Rucaparib

The Basics

What is Rucaparib?

Used to help maintain the response to other treatments for certain types of ovarian cancer, fallopian tube, and primary peritoneal cancer.

Brand names for Rucaparib

Rubraca Tablets

How Rucaparib is classified

Antineoplastic Agents, Enzyme Inhibitors, Signal Transduction Inhibitors, PARP Inhibitors

Rucaparib During Pregnancy

Rucaparib pregnancy category

Category Not AssignedNote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Rucaparib while pregnant

Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC0-24h in patients receiving the recommended dose of 600 mg twice daily . Apprise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In a dose range-finding embryo-fetal development study, pregnant rats received oral doses of 50, 150, 500, or 1000 mg/kg/day of rucaparib during the period of organogenesis. Post-implantation loss (100% early resorptions) was observed in all animals at doses greater than or equal to 50 mg/kg/day (with maternal systemic exposures approximately 0.04 times the human exposure at the recommended dose based on AUC0-24h).

Taking Rucaparib While Breastfeeding

What are recommendations for lactation if you're taking Rucaparib?

No information is available on the clinical use of rucaparib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during rucaparib therapy and for 2 weeks following therapy.

Maternal / infant drug levels

No information is available on the clinical use of rucaparib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during rucaparib therapy and for 2 weeks following therapy.

Possible effects of Rucaparib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Rucaparib

None listed